Burstein A H, Wyble L E, Gal P, Diaz P R, Ransom J L, Carlos R Q, Forrest A
Division of Neuropharmacology, Dent Neurologic Institute, Millard Fillmore Hospital, Buffalo, New York 14209.
Antimicrob Agents Chemother. 1994 Sep;38(9):2024-8. doi: 10.1128/AAC.38.9.2024.
The objective of the reported study was to characterize the pharmacokinetics of ticarcillin and clavulanic acid in premature low-birth-weight (less than 2,200 g) neonates with presumed sepsis. Eleven infants received 12 courses of ticarcillin-clavulanic acid at 75 mg/kg of body weight intravenously every 12 h. Blood samples were collected at 0.5, 1.5, 4, and 8 h following the infusion of the initial dose. The concentrations of ticarcillin and clavulanic acid were determined by a microbiologic assay. Median (interpatient coefficients of variation) values for the volume of the central compartment, total steady-state volume, distributional clearance, total clearance, and terminal elimination half-life for ticarcillin were 0.030 liter/kg (21%), 0.26 liter/kg (48%), 0.41 liter/h/kg (47%), 0.047 liter/h/kg (47%), and 4.2 h (45%), respectively. For clavulanic acid the parameters were 0.28 liter/kg (32%), 0.36 liter/kg (34%), 11 liters/h/kg (36%), 0.12 liters/h/kg (72%), and 1.95 h (40%), respectively. Our results suggest that the current dosing recommendations of 75 mg/kg every 12 h risk subtherapeutic clavulanic acid concentrations and that 50 mg/kg every 6 h is a more rational dosing strategy.
该报告研究的目的是描述替卡西林和克拉维酸在疑似败血症的早产低体重(小于2200克)新生儿中的药代动力学特征。11名婴儿接受了12个疗程的替卡西林-克拉维酸治疗,剂量为每12小时静脉注射75毫克/千克体重。在输注初始剂量后的0.5、1.5、4和8小时采集血样。替卡西林和克拉维酸的浓度通过微生物测定法测定。替卡西林中央室容积、总稳态容积、分布清除率、总清除率和末端消除半衰期的中位数(患者间变异系数)值分别为0.030升/千克(21%)、0.26升/千克(48%)、0.41升/小时/千克(47%)、0.047升/小时/千克(47%)和4.2小时(45%)。对于克拉维酸,这些参数分别为0.28升/千克(32%)、0.36升/千克(34%)、11升/小时/千克(36%)、0.12升/小时/千克(72%)和1.95小时(40%)。我们的结果表明,目前每12小时75毫克/千克的给药建议有导致克拉维酸浓度低于治疗水平的风险,每6小时50毫克/千克是一种更合理的给药策略。